

Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022

<https://marketpublishers.com/r/B2964BD1B97EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: B2964BD1B97EN

Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight's, "Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022" report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Beta Selective Thyroid Hormone Receptor Agonist Understanding

Beta Selective Thyroid Hormone Receptor Agonist: Overview

Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. A lack of thyroid hormones is not compatible with normal health. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TR α and TR β , with the TR α isoform known to be responsible for the main beneficial effects of TH on liver. In brain, despite the crucial role of TR α isoform in neuronal development, TR β has been proposed to play a role in the remyelination processes. TR β is the predominant isoform of TR in the liver and therefore is primarily responsible for the reduction of cholesterol levels, whereas the

adverse effects on heart and bone are mainly connected to TR?. Thus, in the development of clinically useful drug candidates, much effort has been directed toward the design of compounds with isomer-specific activity related to the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TR? selective.

'Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape is provided which includes the disease overview and Beta Selective Thyroid Hormone Receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth Beta Selective Thyroid Hormone Receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta Selective Thyroid Hormone Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Beta Selective Thyroid Hormone Receptor Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Beta Selective Thyroid Hormone Receptor Agonist.

Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs Chapters

This segment of the Beta Selective Thyroid Hormone Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs

Resmetirom: Madrigal Pharmaceuticals

Resmetirom (MGL-3196) is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β -selective agonist. Preclinical, toxicology, Phase I, and Phase II clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and associated dyslipidemias. It is currently in Phase III stage of development.

VK2809: Viking Therapeutics

VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

Further product details are provided in the report.....

Beta Selective Thyroid Hormone Receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Beta Selective Thyroid Hormone Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Beta Selective Thyroid Hormone Receptor Agonist

There are approx. 14+ key companies which are developing the therapies for Beta Selective Thyroid Hormone Receptor Agonist. The companies which have their Beta Selective Thyroid Hormone Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, Madrigal Pharmaceuticals.

Phases

DelveInsight's report covers around 14+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Beta Selective Thyroid Hormone Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beta Selective Thyroid Hormone Receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta Selective Thyroid Hormone Receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta Selective Thyroid Hormone Receptor Agonist drugs.

Beta Selective Thyroid Hormone Receptor Agonist Report Insights

Beta Selective Thyroid Hormone Receptor Agonist Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Beta Selective Thyroid Hormone Receptor Agonist Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Beta Selective Thyroid Hormone Receptor Agonist drugs?

How many Beta Selective Thyroid Hormone Receptor Agonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta Selective Thyroid Hormone Receptor Agonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta Selective Thyroid Hormone Receptor Agonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Beta Selective Thyroid Hormone Receptor Agonist and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Madrigal Pharmaceuticals

Ascleptis

Eccogene

Viking Therapeutics

Aligos Therapeutics

Autobahn Therapeutics

Terns Pharmaceuticals

Viking Therapeutics

Key Products

Resmetirom

ASC-41

Research programme: thyroid hormone receptor beta agonists

VK2809

ALG-055009

ABX-002

TERN-501

VK 0214

Contents

Introduction

Executive Summary

Beta Selective Thyroid Hormone Receptor Agonist: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

- Comparative Analysis

Resmetirom: Madrigal Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

VK2809: Viking Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I)

- Comparative Analysis

ASC-41: Ascleptis

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Preclinical stage products

- Comparative Analysis

ALG-055009: Aligos Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Beta Selective Thyroid Hormone Receptor Agonist Key Companies

Beta Selective Thyroid Hormone Receptor Agonist Key Products

Beta Selective Thyroid Hormone Receptor Agonist- Unmet Needs

Beta Selective Thyroid Hormone Receptor Agonist- Market Drivers and Barriers

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/B2964BD1B97EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2964BD1B97EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970